866-997-4948(US-Canada Toll Free)

Global Antiemetic Drug Market 2017-2021

Published By :

Technavio

Published Date : Jun 2017

Category :

Metabolic Disorders

No. of Pages : 70 Pages

About Antiemetic Drug
Emesis is defined as forceful expulsion of stomach content either due to humoral stimulation due to chemoreceptor trigger zone (CRTZ) or neural stimulation of emetic centers. The various drugs that are used to treat this condition of emesis are known as antiemetics. The various classes of drug available for management of emesis are serotonin antagonist, dopamine antagonist, NK1 receptor antagonist, antihistaminic, steroids, and anticholinergic. The various applications of antiemetic drugs include chemotherapy, surgery, gastroenteritis, morning sickness, motion sickness, stress-induced emesis, and drugs-induced emesis. This market is primarily volume driven as majority of drugs are available in generic form.

Technavios analysts forecast the global antiemetic drug market to grow at a CAGR of 6.13% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global antiemetic drug market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Antiemetic Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Johnson & Johnson
Pfizer
Sanofi
Other prominent vendors
Abbott
Bristol-Myers Squibb
Cipla
Eisai
Eli Lilly
Glenmark
Helsinn Healthcare
Heron Therapeutics
IPCA Laboratories
Lupin
Merck
Novartis
RedHill
Sun Pharmaceutical Industries
Takeda Pharmaceutical
Market driver
Increased prevalence of cancer
For a full, detailed list, view our report

Market challenge
Lack of animal models
For a full, detailed list, view our report

Market trend
Inorganic growth strategies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: An overview of emesis
PART 06: Market landscape
Market overview
Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by application
Chemotherapy
Surgery
Gastroenteritis
Others
PART 09: Market segmentation by drug class
5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
Dopamine antagonist
Neurokinin-1 (NK 1) receptor antagonist
Cannabinoid receptor antagonist
Others
PART 10: Geographical segmentation
Antiemetic drug market in Americas
Antiemetic drug market in EMEA
Antiemetic drug market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
Market drivers
Market challenges
PART 13: Market trends
Inorganic growth strategies
Guidelines for CINV drug development
Antiemetic oral soluble films
PART 14: Vendor landscape
Competitive scenario
PART 15: Key vendor analysis
GlaxoSmithKline
Johnson & Johnson
Pfizer
Sanofi
Other prominent vendors
PART 16: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Application of antiemetic drugs
Exhibit 02: Major antiemetic drug class
Exhibit 03: Global antiemetic drugs market snapshot 2016
Exhibit 04: Steps involved in emesis
Exhibit 05: Mechanism of emesis
Exhibit 06: Causes of emesis
Exhibit 07: Global antiemetic drug market snapshot
Exhibit 08: Global antiemetic drugs market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global antiemetic drugs market
Exhibit 10: Five forces analysis
Exhibit 11: Pipeline analysis of vendors in Phase I
Exhibit 12: Pipeline analysis of vendors in Phase II
Exhibit 13: Pipeline analysis of vendors in Phase III
Exhibit 14: Key clinical trials
Exhibit 15: Market segmentation by application 2016
Exhibit 16: Global antiemetic chemotherapeutic drugs market 2016-2021 ($ millions)
Exhibit 17: Global antiemetic surgery treatment market 2016-2021 ($ millions)
Exhibit 18: Global antiemetic gastroenteritis drugs market 2016-2021 ($ millions)
Exhibit 19: Various emetics symptoms
Exhibit 20: Global antiemetic other drugs market 2016-2021 ($ millions)
Exhibit 21: Segmentation of global antiemetic drugs market by drug class 2016
Exhibit 22: Other drug classes of antiemetic drugs market
Exhibit 23: Segmentation of global antiemetic drugs market by geography 2016 and 2021
Exhibit 24: Segmentation of global antiemetic drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 25: Market scenario in Americas
Exhibit 26: Antiemetic drugs market in Americas 2016-2021 ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: Antiemetic drugs market in EMEA 2016-2021 ($ millions)
Exhibit 29: Market scenario in APAC
Exhibit 30: Antiemetic drugs market in APAC 2016-2021 ($ millions)
Exhibit 31: Factors causing PONV
Exhibit 32: Triggers and therapeutics for CINV
Exhibit 33: Revenue of Kytril marketed by F. Hoffmann-La Roche 2014-2016 ($ millions)
Exhibit 34: Competitive structure analysis of global antiemetic drug market 2016
Exhibit 35: Competitive factors of global antiemetic drugs market
Exhibit 36: Market penetration of various global antiemetic drugs manufacturers 2016
Exhibit 37: Strategic success factors of companies in global antiemetic drugs market
Exhibit 38: GSK: Key highlights
Exhibit 39: GlaxoSmithKline: Strength assessment
Exhibit 40: GlaxoSmithKline: Strategy assessment
Exhibit 41: GlaxoSmithKline: Opportunity assessment
Exhibit 42: Johnson & Johnson: Key highlights
Exhibit 43: Johnson & Johnson: Strength assessment
Exhibit 44: Johnson & Johnson: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment
Exhibit 50: Sanofi: Key highlights
Exhibit 51: Sanofi: Strength assessment
Exhibit 52: Sanofi: Strategy assessment
Exhibit 53: Sanofi opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *